Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of cyclophosphamide-mediated regulatory T-cell depletion with TroVax vaccination in metastatic colorectal cancer
2010-024380-41Phase 2Completed
- Sponsor
- Cardiff University
- Start
- May 2011
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of MVA-5T4 and cyclophosphamide in colorectal cancer (CRC) (4 arms), sponsored by Cardiff University. Primary endpoints: Anti-5T4 T-cell response and Anti-5T4 B-cell response. Started May 2011; status: completed.
02
Drugs
MVA-5T4cyclophosphamide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-024380-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024380-41.